ABIO ARCA biopharma, Inc.

2.63
-0.08  -2.78%
Previous Close 2.70
Open 2.80
Price To book 0.93
Market Cap 23.84M
Shares 9,082,000
Volume 36,039
Short Ratio 1.87
Av. Daily Volume 33,277

SEC filingsSee all SEC filings

  1. 8-K - Current report 17533774
  2. 424B5 - Prospectus [Rule 424(b)(5)] 17523364
  3. 8-K - Current report 17523352
  4. 8-K - Current report 161995368
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161995172

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b interim analysis due 3Q 2017.
Gencaro - GENETIC-AF trial
Chronic Heart Failure

Latest News

  1. ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  2. ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial
  3. ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
  4. ARCA BIOPHARMA TO PRESENT AT BIOTECH SHOWCASE 2017
  5. ARCA BIOPHARMA TO PRESENT AT BIOTECH SHOWCASE 2017
  6. ARCA biopharma to Present at Biotech Showcase 2017
  7. ARCA BIOPHARMA, INC. Financials
  8. StockNewsNow.com Publishes New SNNLive Video Interview with ARCA biopharma, Inc. Provides Company Overview and Discusses Clinical Development
  9. ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
  10. ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report
  11. ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2016 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
  12. ARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business Update
  13. ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  14. ARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial
  15. ARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial
  16. ARCA biopharma to Present at the Dawson James Securities Second Annual Growth Stock Conference
  17. ARCA biopharma to Present at the Dawson James Securities Second Annual Growth Stock Conference
  18. ARCA biopharma Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award
  19. ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  20. ARCA biopharma Announces 100th Patient Randomized into the Genetic-AF Phase 2B/3 Clinical Trial

SEC Filings

  1. 8-K - Current report 17533774
  2. 424B5 - Prospectus [Rule 424(b)(5)] 17523364
  3. 8-K - Current report 17523352
  4. 8-K - Current report 161995368
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161995172
  6. 8-K - Current report 161924961
  7. CT ORDER - Confidential treatment order 161884519
  8. 8-K - Current report 161841101
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161818603
  10. 8-K - Current report 161818462